No significant difference according to ER expression levels was observed for distant relapse-free survival (DRFS) (5-years DRFS 77.3% versus 75.6% for patients with ER-negative and ER low positive BC, respectively; log-rank p = 0.500; Fig. 1b) and overall survival (OS) (5-years OS 82.3% versus 76.7% for patients with ER-negative and ER low positive BC, respectively; log-rank p = 0.800; Fig. 1c). The gene discussed is ESR1; the disease is breast cancer.